Table S1. Details of anticoagulant therapy for the AC+ patients.

n = 25	*Date of enrollement*	*Indication for AC*	*Type and dose of AC*	*Date of last F-UP*	*AC continued at last F-UP*	*If discontinued: date of discontinuation*	*If switched: date and new type of AC*	*Duration concomitant use of AC and antifibrotic drugs (in days)*
1	2022-05-26	AF	Apixaban 5 mg bid	2024-11-30	yes			919
2	2022-07-20	AF	Edoxaban 60 mg	2024-07-11	yes			722
3	2022-07-22	AF	Dabigatran 110 mg	2024-11-30	yes			862
4	2022-08-24	AF	Apixaban 5 mg bid	2024-11-30	yes			829
5	2022-08-31	AF	Rivaroxaban 20 mg	2024-11-30	yes			822
6	2022-08-31	AF	Edoxaban 30 mg	2024-05-21	yes			629
7	2022-11-01	AF	Edoxaban 30 mg	2024-11-30	yes			760
8	2022-11-04	AF	Apixaban 5 mg bid	2024-11-30	yes			757
9	2022-11-26	AF	Apixaban 5 mg bid	2024-11-30	yes			735

10	2023-01-25	AF	Rivaroxaban 20 mg	2023-12-09	yes			318
11	2023-04-01	DVT	Rivaroxaban 15 mg bid	2024-11-30	no	2023-07-01	Switched to Edoxaban 60 mg for PE from 25/09/2024	91 (Rivaroxaban + antifibrotic drug) + 66 (Edoxaban + antifibrotic drug)
12	2023-07-07	DVT	Fondaparinux 5 mg	2024-11-30	yes			512
13	2023-07-19	PE	Apixaban 2,5 mg bid	2024-11-30	yes			500
14	2023-07-21	AF	Rivaroxaban 20 mg	2024-03-04	yes			227
15	2023-08-01	PE	Edoxaban 60 mg	2024-11-30	yes			247
16	2023-09-29	PE	Edoxaban 30 mg	2023-10-26	yes			27
17	2023-10-01	PE	Rivaroxaban 10 mg	2024-11-30	yes			426
18	2023-10-05	AF	Edoxaban 30 mg	2024-03-26	yes			173

19	2023-10-30	AF	Rivaroxaban 10 mg	2024-11-30	yes	397
20	2023-11-21	AF	Apixaban 5 mg bid	2024-11-30	yes	375
21	2024-01-15	AF	Apixaban 5 mg bid	2024-11-30	yes	320
22	2024-04-08	AF	Rivaroxaban 10 mg	2024-11-30	yes	236
23	2024-04-24	AF	Enoxaparin 8000 mg bid	2024-11-30	yes	220
24	2024-05-20	DVT	Rivaroxaban 10 mg	2024-11-30	yes	194
25	2024-05-22	DVT	Edoxaban 60 mg	2024-11-30	yes	192

AC: anticoagulant drug; AF: atrial fibrillation; DVT: deep vein thrombosis; PE: pulmonary embolism; BID: bis in die.